Cargando…

Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine

The administration of viral vectored vaccines remains one of the most effective ways to respond to the ongoing novel coronavirus disease 2019 (COVID-19) pandemic. However, pre-existing immunity to the viral vector hinders its potency, resulting in a limited choice of viral vectors. Moreover, the bas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zeyu, Paes, Barbara Cristina Martins Fernandes, Fulber, Julia Puppin Chaves, Tran, Michelle Yen, Farnós, Omar, Kamen, Amine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143285/ https://www.ncbi.nlm.nih.gov/pubmed/37112753 http://dx.doi.org/10.3390/vaccines11040841

Ejemplares similares

Titration methods for rVSV-based vaccine manufacturing
por: Gélinas, Jean-François, et al.
Publicado: (2020)

Bioreactor production of rVSV‐based vectors in Vero cell suspension cultures
por: Kiesslich, Sascha, et al.
Publicado: (2021)

Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures
por: Fulber, Julia Puppin Chaves, et al.
Publicado: (2021)

Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
por: Youssef, Maryam, et al.
Publicado: (2023)

Optimizing expression of functional HIV envelopes in rVSV-ΔG vaccine vectors
por: Wright, KJ, et al.
Publicado: (2012)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization()
por: Dahlke, Christine, et al.
Publicado: (2017)

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
por: Cross, Robert W., et al.
Publicado: (2020)

Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate
por: Makovitzki, Arik, et al.
Publicado: (2021)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
por: Pinski, Amanda N., et al.
Publicado: (2020)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
por: Cao, Wenguang, et al.
Publicado: (2023)

Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use
por: Fulber, Julia P. C., et al.
Publicado: (2022)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
por: Yahalom-Ronen, Yfat, et al.
Publicado: (2022)

Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa
por: Farnós, Omar, et al.
Publicado: (2020)

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
por: Jelinski, Joseph, et al.
Publicado: (2023)

Transcriptomic analysis reveals a previously unknown role for CD8(+) T-cells in rVSV-EBOV mediated protection
por: Menicucci, Andrea R., et al.
Publicado: (2017)

Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor
por: Ton, Christopher, et al.
Publicado: (2023)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus
por: Dong, Fangfang, et al.
Publicado: (2019)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
por: Sorvillo, Teresa E., et al.
Publicado: (2021)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs
por: Madar-Balakirski, Noa, et al.
Publicado: (2022)

Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots
por: Gillespie, Paul F., et al.
Publicado: (2023)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
por: Fuchs, JD, et al.
Publicado: (2012)

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
por: Henao-Restrepo, Ana Maria, et al.
Publicado: (2017)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
por: Gsell, Pierre-Stéphane, et al.
Publicado: (2017)

Author Correction: Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
por: Davis, Chris, et al.
Publicado: (2019)

Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus
por: Ding, Limin S., et al.
Publicado: (2022)

Monitoring Group Activity of Hamsters and Mice as a Novel Tool to Evaluate COVID-19 Progression, Convalescence, and rVSV-ΔG-Spike Vaccination Efficacy
por: Melamed, Sharon, et al.
Publicado: (2021)

rVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits
por: Rosner, Amir, et al.
Publicado: (2022)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

Targeted Delivery of Chimeric Antigen Receptor into T Cells via CRISPR-Mediated Homology-Directed Repair with a Dual-AAV6 Transduction System
por: Moço, Pablo D., et al.
Publicado: (2023)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
por: Legardy-Williams, Jennifer K., et al.
Publicado: (2020)

Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model
por: Lee, Ha-Na, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hrrgb27fsn6da22lhbr5t13ged